Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer)

Nicole Skoetz, Marius Goldkuhle, Gerald Gartlehner, Ina Monsef, Philipp Dahm, Jan Peter Glossmann, Andreas Engert, Bastian von Tresckow

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows: To assess the benefits and harms of nivolumab in adult individuals with Hodgkin lymphoma (HL).

Original languageEnglish (US)
Article numberCD012556
JournalCochrane Database of Systematic Reviews
Volume2017
Issue number2
DOIs
StatePublished - Feb 17 2017

Fingerprint Dive into the research topics of 'Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer)'. Together they form a unique fingerprint.

  • Cite this

    Skoetz, N., Goldkuhle, M., Gartlehner, G., Monsef, I., Dahm, P., Glossmann, J. P., Engert, A., & von Tresckow, B. (2017). Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer). Cochrane Database of Systematic Reviews, 2017(2), [CD012556]. https://doi.org/10.1002/14651858.CD012556